Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.